Performance Study of Targeted Sequencing Technology for VAP

Launched by THE FIRST HOSPITAL OF JILIN UNIVERSITY · Sep 6, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a new testing method called targeted next-generation sequencing (tNGS) to help identify the germs causing Ventilator Associated Pneumonia (VAP) and to see if they are resistant to certain medications. VAP is a lung infection that can occur in patients on ventilators. The study will take place in hospitals and will involve collecting samples from the lungs of patients diagnosed with VAP. Researchers will compare the results from this new testing method with standard tests that are currently used, which include cultures (growing germs from a sample), microscopy, and other laboratory tests.

To participate in this study, patients must be diagnosed with VAP and able to provide necessary test information. Unfortunately, those who have been diagnosed with a non-infectious condition, are unable to provide samples, or have a life expectancy of less than 24 hours will not be eligible. The trial is not yet recruiting participants, but those who join can expect to undergo some routine testing along with the new tNGS method to help improve the diagnosis and treatment of VAP in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • (1)VAP patients (2) Patients can collect the required test information
• Exclusion Criteria:
• • (1) Clearly diagnosed as non-infectious patients
• • (2) Insufficient samples or patients unwilling to participate
• • (3) Life expectancy is less than 24 hours
• • (4) Patients' clinical information cannot be obtained